SUPPLEMENTARY INFORMATION:

Intellectual Property

1. U.S. Provisional Application No. 61/299,790, filed January 29, 2010 which is entitled “Caspase Inhibitors” (HHS Ref. No. E-308-2009-0-US-01);

2. International Patent Application No. PCT/US2011/02274 filed on January 27, 2011 which is entitled “Caspase Inhibitors” (HHS Ref. No. E-308-2009-0-PCT-02); and

3. US Patent Application No. 13/575,273 filed on July 25, 2012 which is entitled “Caspase Inhibitors” and issued as U.S. Patent No. 9,365,612 (HHS Ref. No. E-308-2009-0-US-03).

The patent rights in these inventions have been either assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the following:

“Development, manufacture, use and commercialization of Caspase Inhibitors ( printed page 47153) disclosed and claimed in the prospective licensed patent rights, for the treatment of inflammatory diseases, such as hidradenitis suppurativa (HS) in humans and animals.”

The subject technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Several cyanopropanate containing small molecules were synthesized, including one based upon the optimized peptidic scaffold of the prodrug VX-765. A number of these compounds were potent inhibitors of caspase 1 (IC50s ≤ 1 nM). Examination of these small molecules versus a caspase panel demonstrated an impressive degree of selectivity for caspase 1 inhibition. The small molecular probe ML132 (CID-4462093; NCGC-00183434) is the most potent caspase 1 inhibitor reported to date. It also possesses a unique selectivity pattern relative to other reported caspase inhibitors. A number of these compounds were assessed for their hydrolytic stability and selected absorption, distribution, metabolism and elimination (ADME) properties. Some of the compounds of this invention could be developed as effective therapeutics for diseases such as inflammatory diseases such as hidradenitis suppurativa (HS), ischemic disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and sepsis.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Center for Advancing Translational Sciences receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.